Introduction

Thyroid cancer is a malignant thyroid neoplasm originating from follicular or parafollicular thyroid cells (Xing, 2013). In recent decades, thyroid cancer is a common endocrine malignancy that has rapidly increased in global incidence (Jemal et al., 2011), and it now is increasing faster than other malignancy (Xie et al., 2012; Siegel et al., 2013). Although the death rate of thyroid cancer is relatively low, the rate of disease recurrence is high, which is associated with increased patient morbidity and mortality (Tuttle et al., 2010). Certainly, a greater understanding of the molecular mechanisms that lead to the formation of thyroid cancer is needed if better methods of prevention, detection, and treatment are to be developed.

The B7-H4 coregulatory molecule is a member of the B7 family of molecules, which play a central role in the regulation of antigen-specific T cell-mediated immune responses. B7-H4, also referred to as B7x or B7S1, is a ligand within the B7 family that has been implicated as a negative regulator of T cell-mediated immunity. Robust B7-H4 protein expression is primarily restricted to activated T cells, B cells, dendritic cells, and monocytes. Weak expression of B7-H4 has also been observed in some peripheral tissues, presumably surveyed from human autopsy specimens or tissues that were removed because of pathologic conditions not directly involving the organ being examined. Recently, B7-H4 has been reported to be highly expressed in human cancer cells, and their protein levels in tumors significantly correlate with patients’ clinicopathological features and postoperative prognosis (Miyatake et al., 2007; Awadallah et al., 2008; Arigami et al., 2011; Abadi et al., 2013). However, no reports have investigated the clinical significance of B7-H4 expression in patients with thyroid cancer.

In the present study, we investigated tumor microenvironment by examining B7-H4 protein expression as well as densities of various TIL subsets in human thyroid cancer tissues using the immunohistochemical method. B7-H4 expression in relation to patients’ clinicopathological parameters and densities of TILs was analyzed. Prognostic values of B7-H4 were evaluated in a log-rank survival analysis. Our results showed that expression levels of the inhibitory costimulatory molecule B7-H4 in human thyroid cancer tissues were significantly correlated with cancer progression, densities of TILs, and poorer patient outcome.

Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine, Shanghai, China *Equal contributors *For correspondence: shenglaizhang@hotmail.com

RESEARCH ARTICLE

B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

Jian Zhu, Bing-Feng Chu, Yi-Peng Yang, Sheng-Lai Zhang*, Ming Zhuang, Wen-Jie Lu, Ying-Bin Liu

Abstract

Objective: This study aimed to investigate the expression of B7-H4 in human thyroid cancer and determine any association with patient clinicopathological parameters and survival. Methods: B7-H4 expression in 64 clinical thyroid cancer specimens was assessed with immunohistochemistry. Moreover, B7-H4 mRNA expression in 10 fresh resected specimens were evaluated by the reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical staining of CD3 was performed to assess the number of tumor infiltrating T lymphocytes (TILs) in thyroid cancers. Results: Positive B7-H4 immunohistochemical staining was observed in 61 out of 64 (95.3%) specimens of thyroid cancer tissues. Significantly more B7-H4 mRNA copies were found in thyroid cancer tissue than that adjacent normal tissue. Moreover, B7-H4 expression in human thyroid cancer tissues was significantly correlated with patient TNM stages and extrathyroidal extension (P<0.05), being inversely correlated with the number of TILs (P<0.05). The overall survival rate of the patients with higher B7-H4 expression was significantly worse than that of the patients with lower B7-H4 expression. Conclusions: This present study suggests that high B7-H4 expression is associated with cancer progression, reduced tumor immunosurveillance and worse patient outcomes in human thyroid cancer.

Keywords: Thyroid cancer - B7-H4 - progression - prognosis - tumor infiltrating lymphocytes

Asian Pacific J Cancer Prev, 14 (5), 3011-3015

Asian Pacific Journal of Cancer Prevention, Vol 14, 2013 3011
Materials and Methods

Patient population

Formalin-fix, paraffin-embedded tumor tissue blocks were collected retrospectively from the Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine. All of the 64 thyroid cancer patients underwent surgical resection between December 2006 and August 2008 in Xinhua hospital. None of the patients received chemotherapy or radiotherapy before surgery. The pathologic reports were reviewed, and the tumor–node–metastasis (TNM) stages were assigned according to the American Joint Committee on Cancer staging system. Patients’ clinical parameters are shown in Table 1, and patients’ survival intervals are dated toward the end of December 2012. In addition, 8 normal tissues from the non-malignant portion of thyroid were resected from surgery and used as controls. Ethical approval for this study was granted by the ethics committee of Xinhua hospital and informed consents were obtained.

Immunohistochemical staining

B7-H4 expression was analyzed using human thyroid cancer and normal tissue. Standard immunohistochemical procedures were carried out using VECTASTAIN Elite ABC system (Vector Laboratories, USA), according to the manufacturer’s protocol. Anti-B7-H4 monoclonal antibody (Abcam, USA) was used as a primary antibody. Similar tissue sections were immunostained with normal IgG were used as negative controls. In the immunohistochemical procedure for CD3, anti-human CD3 antibody (DAKO, USA) diluted 1:100 in PBS was used. The specimens were examined and scored using a two-headed microscope. Staining intensity (0, no staining; 1, weak staining; 2, moderate staining; and 3, intense staining) and the proportion of stained cells (0, no staining; 1, <10% staining; 2, between 11% and 33%; 3, between 34% and 66%; and 4, >67%) were semi-quantitatively determined. The intensity and percentage of positive cell scores were multiplied (0-12). All slides were scored by two observers blinded to the pathology and clinical features. There are good concordances between two observers. In cases where score difference was equal to or exceeding 2, the slides were re-examined and a consensus was reached by the observers. Mean score for duplicate cores from each individual was calculated.

Quantitative RT-PCR

Fresh tumor specimens were homogenized in FastPrep (Qbiogene, USA). Quantitative real-time PCR (qRT-PCR) analysis was carried out to detect the expression of B7-H4 in 10 human thyroid cancer tissues and corresponding adjacent normal tissues. Total RNA extraction from thyroid cancer tissue was performed with Trizol Reagent (Invitrogen). Then, 2 μg of total RNA was reverse-transcribed with Taqman (TakaRa PrimeScript™ RT Reagent Kit, Japan). The primers below were used to amplify B7-H4 and GAPDH. B7-H4: (Forward), 5'-CTTCGTGCTCCTGACCCTTA-3’; (Reverse), 5'-GACTGTGGTCATGCTCT-3’. Each reaction had a total volume of 25 μl, with reagents from the TakRaEx Taq™ kit. Thermocycling conditions included 40 cycles of denaturing at 94°C for 30 s, annealing at 55°C for 15 s and extension at 72°C for 60 s. Data from the array were normalized to GAPDH.

Statistical analysis

All statistics were performed with the GraphPad Prism version 5.0 for Windows (GraphPad Software, USA). The χ² test was used to assess the statistical significance of differences between the various tissue specimens. Correlation between variables was evaluated by Spearman’s rank correlation coefficients. Survival analysis was carried out using the Kaplan-Meier method and log-rank test. Differences were considered to be statistically significant at P<0.05.

Results

B7-H4 expression in human thyroid cancer tissues

The B7-H4 expression in 64 tissue specimens obtained from patients with thyroid cancer was assessed by immunohistochemical staining. Interobserver agreement in the assessment of immunohistochemical findings was excellent. Positive B7-H4 immunohistochemical staining was predominantly observed on the membrane and in cytoplasm of thyroid cancer cells (Figure 1), while weak staining was found in normal thyroid tissues. 61 out of 64 (95.3%) specimens of thyroid cancer tissues showed positive B7-H4 staining. Therefore, higher B7-H4 expression was identified in 46 (71.9%) of 64 thyroid cancer specimens. In this study, B7-H4 expression in 20 fresh tumor specimens from thyroid cancer patients was also assessed with the RT-PCR assay. In clinical thyroid tissues, B7-H4 mRNA expression was confirmed in all of tumor specimens and higher B7-H4 mRNA expression was found in tumor tissues than that in adjacent normal tissues (P<0.01) (Figure 2).

Figure 1. Representative Immunohistochemical Staining of B7-H4 Expression in Thyroid Cancer Tissues. Tumor cells with negative (A), weak (B), moderate (C), and strong (D) expression of B7-H4. Immunohistochemistry showed that positive B7-H4 immunohistochemical staining was predominantly observed on the membrane and in cytoplasm of tumor cells. Original magnification ×400.
The level of B7-H4 protein was positively correlated with metastasis (P<0.05), whereas it is not correlated with patient’s age, gender, tumor sizes, and lymph node metastasis. It is inversely correlated with the number of tumor infiltrating T lymphocytes (P<0.01). Horizontal bars indicate the mean number of tumor infiltrating T lymphocytes.

To further investigate the clinical relevance of B7-H4 expression and tumor immune surveillance, the number of tumor infiltrating T lymphocytes was assessed by CD3 immunohistochemical staining. TILs stained by CD3 antigen were diffusely identified in thyroid foci and stroma (Figure 3A). The number of TILs was significantly lower in thyroid cancer patients with high B7-H4 expression (66.4 ± 36.2) than those in patients with low B7-H4 expression (101.7 ± 54.7) (P<0.01) (Figure 3B). Consequently, the B7-H4 expression status of thyroid cancer cells was inversely correlated with the number of tumor infiltrating T lymphocytes (P<0.01).

**Correlation between tumor cell B7-H4 expression and densities of TILs**

To investigate the relationship between B7-H4 expression and tumor immune surveillance, we categorized 64 patients into two major subgroups according to the intensity of B7-H4 immunohistochemical staining, i.e., the lower B7-H4 expression group (score ≤ 6, 18 cases), and the higher B7-H4 expression group (score > 6, 46 cases). The correlation between tumor cell B7-H4 expression and patients’ clinicopathologic parameters was shown in Table 1. It demonstrated that B7-H4 expression in human thyroid cancer tissues was significantly correlated with patient’s TNM stage (P<0.05) and extrathyroidal extension (P<0.05), whereas it is not correlated with patient’s age, gender, tumor sizes, and lymph node metastasis. It is worth mentioning that there was a trend toward a positive correlation between B7-H4 expression and lymph node metastasis (P = 0.08). Thus, our data demonstrated that the level of B7-H4 protein was positively correlated with advanced clinicopathological parameters and supported that B7-H4 was involved in the progression of human thyroid cancer.

**High B7-H4 expression associated with poor prognosis in human thyroid cancer**

We then evaluated the association between B7-H4 expression and survival following radical cystectomy in thyroid cancer patients. Our data showed that higher expression of B7-H4 is associated with a poor outcome following radical cystectomy (Figure 4). The survival rates were significantly lower in patients with high B7-H4 expression than in those with low B7-H4 expression (P<0.05). Our studies support the utility of B7-H4 as a marker for thyroid cancer progression and patient survival.
prognostic biomarkers for recurrence in thyroid cancer patients undergoing cystectomy.

Discussion

B7-H4 is a member of the B7 gene family, which has been implicated in negatively regulating T cell mediated immunity. Here, we demonstrated that B7-H4 protein was overexpressed in human thyroid cancer tissues but weakly expressed in normal tissues. We also clarified the clinical significance of B7-H4 expression in thyroid cancer by investigating relationships between B7-H4 protein expression and clinicopathological factors including prognosis. We demonstrated that higher B7-H4 expression was positively correlated with advanced TNM stage and poor patient outcome, implicating its role in thyroid cancer progression. To our knowledge, this study is the first to assess B7-H4 expression and to explore its clinical significance in thyroid cancer. We believe that, with further investigation, B7-H4 could become a clinical prognostic marker and a target for immunotherapeutic treatment of human thyroid cancer.

The costimulatory B7 family members are cell-surface protein ligands, binding to receptors on lymphocytes to regulate immune responses (Fliel et al., 2007). They do not only provide positive signals to stimulate T-cell activation, but also regulate negative signals to inhibit T-cell responses. Inhibitory B7 molecules have been demonstrated to be upregulated in different tumors, which may contribute to tumor immune evasion (Chen, 2004). B7-H4, a member of the B7 family, has been identified as a negative regulatory molecule on the cell membrane, which inhibits the proliferation and cytokine production of CD4+ T and CD8+ T cells (Prasad et al., 2003; Sica et al., 2003). In the tumor microenvironment, B7-H4 binds to an unknown receptor on the T cell surface, inhibiting tumor-specific T cell activation and proliferation. Accumulated evidence has shown that increased B7-H4 expression is involved in shaping the tumor microenvironment, and aberrant B7-H4 expression is associated with various clinicopathological features in many human malignancies (Zheng et al., 2012). In gastric cancer, B7-H4 significantly correlated with depth of tumor invasion, lymph node metastasis, and overall stage in gastric cancer (Arigami et al., 2010). B7-H4 expression was significantly higher in invasive breast cancer cells and increased B7-H4 expression was associated with negative progesterone receptor status in breast cancer patients (Tringler et al., 2005). Furthermore, the measurement of B7-H4 expression is expected to become a useful tool in predicting patient outcome in thyroid cancer. Our studies support the utility of B7-H4 as prognostic biomarkers in thyroid cancer patients undergoing cystectomy.

In conclusions, our results demonstrate that B7-H4 expression is involved in thyroid cancer progression and tumor avoidance of immunosurveillance and could be a useful prognostic indicator for human thyroid cancer. Future studies on the biological behavior of thyroid cancer cells expressing B7-H4 may lead to a new immunotherapy blocking its signaling pathway in patients with thyroid cancer.

Acknowledgements

This work was supported by grants from the Key Fund of Shanghai Municipal Health Bureau (20124015). We are grateful to all staffs of department of general surgery in Xinhua hospital for cooperating with us in the sample collection. The authors have no direct or indirect
commercial financial incentive associated with publishing the article.

References

Abadi YM, Jeon H, Ohaegbulam KC, et al (2013). Host b7x promotes pulmonary metastasis of breast cancer. *J Immunol, 190*, 3806-14.

Arigami T, Uenosono Y, Hirata M, et al (2010). Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. *J Surg Oncol, 102*, 748-52.

Arigami T, Uenosono Y, Ishigami S, et al (2011). Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. *World J Surg, 35*, 2051-7.

Awadallah NS, Shroyer KR, Langer DA, et al (2008). Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. *Pancreas, 36*, 200-6.

Chen L (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. *Nat Rev Immunol, 4*, 336-47.

Chen LJ, Sun J, Wu HY, et al (2011). B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. *Cancer Immunol Immunother, 60*, 1047-55.

Flies DB, Chen L (2007). The new B7s: playing a pivotal role in tumor immunity. *J Immunother, 30*, 251-60.

Grabenbauer GG, Lahmer G, Distel L, et al (2006). Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. *Clin Cancer Res, 12*, 3355-60.

Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. *CA Cancer J Clin, 61*, 69-90.

Miyatake T, Tringler B, Liu W, et al (2007). B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. *Gynecol Oncol, 106*, 119-27.

Oikonomopoulou K, Li L, Zheng Y, et al (2008). Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. *Br J Cancer, 99*, 1103-13.

Prasad DV, Richards S, Mai XM, et al (2003). B7S1, a novel B7 family member that negatively regulates T cell activation. *Immunity, 18*, 863-73.

Sica GL, Choi IH, Zhu G, et al (2003). B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. *Immunity, 18*, 849-61.

Siegel R, Naishadham D & Jemal A (2013). Cancer statistics, 2013. *CA Cancer J Clin, 63*, 11-30.

Sun SQ, Jiang CG, Lin Y, et al (2012). Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines. *J Int Med Res, 40*, 497-506.

Tringler B, Zhuo S, Pilkington G, et al (2005). B7-h4 is highly expressed in ductal and lobular breast cancer. *Clin Cancer Res, 11*, 1842-8.

Tuttle RM, Ball DW, Byrd D, et al (2010). Thyroid carcinoma. *J Natl Compr Canc Netw, 8*, 1228-74.

Xie WC, Chan MH, Mak KC, et al (2012). Trends in the incidence of 15 common cancers in Hong Kong, 1983-2008. *Asian Pac J Cancer Prev, 13*, 3911-6.

Xing M (2013). Molecular pathogenesis and mechanisms of thyroid cancer. *Nat Rev Cancer, 13*, 184-99.

Zang X, Loke P, Kim J, et al (2003). B7x: a widely expressed B7 family member that inhibits T cell activation. *Proc Natl Acad Sci USA, 100*, 10388-92.

Zhang L, Wu H, Lu D, et al (2013). The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene, Jan 14. doi: 10.1038/onc.2012.600. [Epub ahead of print].

Zheng X, Li XD, Wu CP, et al (2012). Expression of costimulatory molecule B7-H4 in human malignant tumors. *Onkologie, 35*, 700-5.